These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24236974)

  • 41. Pharmacological small molecules for the treatment of lysosomal storage disorders.
    Smid BE; Aerts JM; Boot RG; Linthorst GE; Hollak CE
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1367-79. PubMed ID: 20942596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological chaperones: a new twist on receptor folding.
    Morello JP; Petäjä-Repo UE; Bichet DG; Bouvier M
    Trends Pharmacol Sci; 2000 Dec; 21(12):466-9. PubMed ID: 11121835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice.
    Sly WS
    Mo Med; 2004; 101(2):100-4. PubMed ID: 15119106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological chaperone therapy for lysosomal storage disorders - leveraging aspects of the folding pathway to maximize activity of misfolded mutant proteins.
    Fan JQ
    FEBS J; 2007 Oct; 274(19):4943. PubMed ID: 17894778
    [No Abstract]   [Full Text] [Related]  

  • 45. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.
    Shayman JA; Larsen SD
    J Lipid Res; 2014 Jul; 55(7):1215-25. PubMed ID: 24534703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral small molecule therapy for lysosomal storage diseases.
    Weinreb NJ
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Enzyme replacement therapy of patients with lysosomal storage disease].
    Takada G; Takahashi T
    Nihon Rinsho; 1995 Dec; 53(12):3077-82. PubMed ID: 8577062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
    Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N
    Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological Chaperones: Beyond Conformational Disorders.
    Leidenheimer NJ
    Handb Exp Pharmacol; 2018; 245():135-153. PubMed ID: 29071508
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biologic activities of molecular chaperones and pharmacologic chaperone imidazole-containing dipeptide-based compounds: natural skin care help and the ultimate challenge: implication for adaptive responses in the skin.
    Babizhayev MA; Nikolayev GM; Nikolayeva JG; Yegorov YE
    Am J Ther; 2012 Mar; 19(2):e69-89. PubMed ID: 20861720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities.
    Hoffmann B; Mayatepek E
    Neuropediatrics; 2005 Oct; 36(5):285-9. PubMed ID: 16217702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemical chaperones: mechanisms of action and potential use.
    Papp E; Csermely P
    Handb Exp Pharmacol; 2006; (172):405-16. PubMed ID: 16610368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Introduction: molecular chaperones of the ER: their role in protein folding and genetic disease.
    Brooks DA
    Semin Cell Dev Biol; 1999 Oct; 10(5):441-2. PubMed ID: 10597626
    [No Abstract]   [Full Text] [Related]  

  • 54. Gaucher disease.
    Butters TD
    Curr Opin Chem Biol; 2007 Aug; 11(4):412-8. PubMed ID: 17644022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Limitations of enzyme replacement therapy: current and future.
    Wraith JE
    J Inherit Metab Dis; 2006; 29(2-3):442-7. PubMed ID: 16763916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity.
    Fan JQ
    Trends Pharmacol Sci; 2003 Jul; 24(7):355-60. PubMed ID: 12871668
    [No Abstract]   [Full Text] [Related]  

  • 57. Protein misfolding disorders: pathogenesis and intervention.
    Gregersen N
    J Inherit Metab Dis; 2006; 29(2-3):456-70. PubMed ID: 16763918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological chaperone therapy for lysosomal storage diseases.
    Parenti G; Moracci M; Fecarotta S; Andria G
    Future Med Chem; 2014 Jun; 6(9):1031-45. PubMed ID: 25068986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Virus-like nanoparticles as enzyme carriers for Enzyme Replacement Therapy (ERT).
    González-Davis O; Villagrana-Escareño MV; Trujillo MA; Gama P; Chauhan K; Vazquez-Duhalt R
    Virology; 2023 Mar; 580():73-87. PubMed ID: 36791560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases.
    Cui Y; Hettinghouse A; Liu CJ
    Cytokine Growth Factor Rev; 2019 Feb; 45():53-64. PubMed ID: 30733059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.